New Antifungal Agents

 

 Buy Article Permissions and Reprints

Two new antifungal agents, voriconazole and caspofungin, are now available for treatment of systemic fungal infections. Voriconazole is an extended-spectrum triazole that is fungicidal for filamentous fungi, including Aspergillus, Scedosporium, Fusarium, Paecilomyces, and is active against all species of Candida. It has become first-line therapy for invasive aspergillosis. Voriconazole is given either by the oral or the intravenous route. Clinicians must be aware of drug-drug interactions and side effects, including visual disturbances and photosensitivity rash that can occur when voriconazole is used. Caspofungin is the first drug available from a new class of antifungal agents, echinocandins, that act to inhibit fungal cell wall synthesis. Caspofungin is fungicidal for all species of Candida and more slowly kills Aspergillus species. Caspofungin, available only for intravenous administration, has minimal side effects and very few drug interactions. The echinocandins will find most use for Candida infections and as second-line therapy for Aspergillus infections.

REFERENCES

• 1 Manavathu E K, Cutright J L, Chandrasekar P H. Organism-dependant fungicidal activities of azoles.  Antimicrob Agents Chemother. 1998;  42 3018-3021
  PubMedGoogle Scholar
• 2 Kauffman C A, Zarins L T. In vitro activity of voriconazole against Candida species.  Diagn Microbiol Infect Dis. 1998;  31 297-300
  CrossrefPubMedGoogle Scholar
• 3 Pfaller M A, Diekema D J, Jones R N et al.. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.  J Clin Microbiol. 2001;  39 3254-3259
  CrossrefPubMedGoogle Scholar
• 4 Pfaller M A, Zhang J, Messer S A et al.. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.  Antimicrob Agents Chemother. 1999;  43 169-171
  PubMedGoogle Scholar
• 5 Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.  J Clin Microbiol. 1998;  36 198-202
  PubMedGoogle Scholar
• 6 Manavathu E K, Cutright J L, Loebenberg D, Chandrasekar D H. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH-56592).  J Antimicrob Chemother. 2000;  46 229-234
  CrossrefPubMedGoogle Scholar
• 7 Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex J H. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.  J Clin Microbiol. 1999;  37 3946-3951
  PubMedGoogle Scholar
• 8 Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.  J Clin Microbiol. 2001;  39 954-958
  CrossrefPubMedGoogle Scholar
• 9 Carrillo A J, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp.  Antimicrob Agents Chemother. 2001;  45 2151-2153
  CrossrefPubMedGoogle Scholar
• 10 Li R K, Ciblak M A, Nordoff N, Pasarell L, Warnock D W, McGinnis M R. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum .  Antimicrob Agents Chemother. 2000;  44 1734-1736
  CrossrefPubMedGoogle Scholar
• 11 Gomez-Lopez A, Cuenca-Estrella M, Monzon A, Rodriquez-Tudela J L. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole, and voriconazole.  J Antimicrob Chemother. 2001;  48 919-921
  CrossrefPubMedGoogle Scholar
• 12 Hoffman H L, Rathbun R C. Review of the safety and efficacy of voriconazole.  Expert Opin Investig Drugs. 2002;  11 409-429
  PubMedGoogle Scholar
• 13 Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen M J, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens.  Antimicrob Agents Chemother. 2002;  46 2546-2553
  CrossrefPubMedGoogle Scholar
• 14 Lazarus H M, Blumer J L, Yanovicjh S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.  J Clin Pharmacol. 2002;  42 395-402
  CrossrefPubMedGoogle Scholar
• 15 Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.  Clin Infect Dis. 2003;  37 728-732
  CrossrefPubMedGoogle Scholar
• 16 Walsh T J, Lutsar I, Driscoll T et al.. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.  Pediatr Infect Dis J. 2002;  21 240-248
  CrossrefPubMedGoogle Scholar
• 17 Johnson L B, Kauffman C A. Voriconazole: a new triazole antifungal agent.  Clin Infect Dis. 2003;  36 630-637
  CrossrefPubMedGoogle Scholar
• 18 Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.  Antimicrob Agents Chemother. 2002;  46 3091-3093
  CrossrefPubMedGoogle Scholar
• 19 Romero A J, Le Pogamp P, Nilsson L-G, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients.  Clin Pharmacol Ther. 2002;  71 226-234
  CrossrefPubMedGoogle Scholar
• 20 Ally R, Schurmann D, Kreisel W et al.. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.  Clin Infect Dis. 2001;  33 1447-1454
  CrossrefPubMedGoogle Scholar
• 21 Walsh T J, Pappas P, Winston D J et al.. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.  N Engl J Med. 2002;  346 225-234
  CrossrefPubMedGoogle Scholar
• 22 Denning D W, Ribaud P, Milpied N et al.. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.  Clin Infect Dis. 2002;  34 563-571
  CrossrefPubMedGoogle Scholar
• 23 Herbrecht R, Denning D W, Patterson T F et al.. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.  N Engl J Med. 2002;  347 408-415
  CrossrefPubMedGoogle Scholar
• 24 Perfect J R, Marr K A, Walsh T J et al.. Voriconazole treatment for less-common, emerging, or refractory fungal infections.  Clin Infect Dis. 2003;  36 1122-1131
  CrossrefPubMedGoogle Scholar
• 25 Denning D W, Griffiths C EM. Mucocutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.  Clin Exp Dermatol. 2001;  26 648-653
  CrossrefPubMedGoogle Scholar
• 26 Potoski B A, Brown J. The safety of voriconazole.  Clin Infect Dis. 2002;  35 1273-1275
  CrossrefPubMedGoogle Scholar
• 27 Tan K KC, Brayshaw N, Oakes M. Investigation into the relationship between plasma voriconazole concentrations and liver function test abnormalities in therapeutic trials (Abstr A18). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago IL; Dec 2001
  Google Scholar
• 28 Ascioglu S, Rex J H, dePauw B et al.. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.  Clin Infect Dis. 2002;  34 7-14
  CrossrefPubMedGoogle Scholar
• 29 Nesky M A, McDougal E C, Peacock Jr J E. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis.  Clin Infect Dis. 2000;  31 673-677
  CrossrefPubMedGoogle Scholar
• 30 Munoz P, Marin M, Tornero P et al.. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy.  Clin Infect Dis. 2000;  31 1499-1501
  CrossrefPubMedGoogle Scholar
• 31 Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report.  J Clin Microbiol. 1998;  36 1436-1438
  PubMedGoogle Scholar
• 32 Poza G, Montoya J, Redondo C et al.. Meningitis caused by Pseudallescheria boydii treated with voriconazole.  Clin Infect Dis. 2000;  30 981-982
  CrossrefPubMedGoogle Scholar
• 33 Jabado N, Casanova J-L, Haddad E et al.. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease.  Clin Infect Dis. 1998;  27 1437-1441
  PubMedGoogle Scholar
• 34 Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen H E, Althous C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole.  Br J Ophthalmol. 2000;  84 932-933
  PubMedGoogle Scholar
• 35 Consigny S, Dhedin N, Datry A, Choquet S, Leblond V, Chosidow O. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient.  Clin Infect Dis. 2003;  37 311-313
  CrossrefPubMedGoogle Scholar
• 36 Friese G, Discher T, Fussle R, Schmalreck A, Lohmeyer J. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease.  AIDS. 2001;  15 2344-2345
  CrossrefPubMedGoogle Scholar
• 37 Deresinski S C, Stevens D A. Caspofungin.  Clin Infect Dis. 2003;  36 1445-1457
  CrossrefPubMedGoogle Scholar
• 38 Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class.  J Antimicrob Chemother. 2003;  51 513-521
  CrossrefPubMedGoogle Scholar
• 39 Bartizal K, Gill C J, Abruzzo G K et al.. In vitro clinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).  Antimicrob Agents Chemother. 1997;  41 2326-2332
  PubMedGoogle Scholar
• 40 Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56952 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.  J Clin Microbiol. 1998;  36 2950-2956
  PubMedGoogle Scholar
• 41 Vazquez J A, Lynch M, Boikov D, Sobel J D. In vitro activity of a new pneumocandin antifungal, L743,872, against azole-susceptible and azole-resistant Candida species.  Antimicrob Agents Chemother. 1997;  41 1612-1614
  PubMedGoogle Scholar
• 42 Pfaller M A, Diekema D J, Messer S A, Hollis R J, Jones R N. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.  Antimicrob Agents Chemother. 2003;  47 1068-1071
  CrossrefPubMedGoogle Scholar
• 43 Arikan S, Lozano-Chiu M, Paetznick V, Rex J H. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.  Antimicrob Agents Chemother. 2001;  45 327-330
  CrossrefPubMedGoogle Scholar
• 44 Bowman J C, Hicks P S, Kurtz M B et al.. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.  Antimicrob Agents Chemother. 2002;  46 3001-3012
  CrossrefPubMedGoogle Scholar
• 45 Pfaller M A, Marco M F, Messer S A, Jones R N. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L743,872), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.  Diagn Microbiol Infect Dis. 1998;  30 251-255
  CrossrefPubMedGoogle Scholar
• 46 Ullmann A J. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.  Curr Med Res Opin. 2003;  19 263-271
  CrossrefPubMedGoogle Scholar
• 47 Stone J A, Holland S D, Wickersham P J et al.. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.  Antimicrob Agents Chemother. 2002;  46 739-745
  CrossrefPubMedGoogle Scholar
• 48 Balani A K, Xu X, Arison B H et al.. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine.  Drug Metab Dispos. 2000;  28 1274-1278
  PubMedGoogle Scholar
• 49 Sable C A, Nguyen B Y, Chodakewitz J A, DiNubile M J. Safety and tolerability of caspofungin acetate in the treatment of fungal infections.  Transpl Infect Dis. 2002;  4 25-30
  CrossrefPubMedGoogle Scholar
• 50 Villanueva A, Gotuzzo E, Arathoon E et al.. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.  Am J Med. 2002;  113 294-299
  CrossrefPubMedGoogle Scholar
• 51 Villanueva A, Arathoon E, Gotuzzo E et al.. A randomized double-blind study of caspofungin versus amphotericin B for the treatment of candidal esophagitis.  Clin Infect Dis. 2001;  33 1529-1535
  CrossrefPubMedGoogle Scholar
• 52 Arathoon E G, Gotuzzo E, Noriega L M et al.. Randomized, double-blind, multi-center study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis.  Antimicrob Agents Chemother. 2002;  46 451-457
  CrossrefPubMedGoogle Scholar
• 53 Mora-Duarte J, Betts R, Rotstein C et al.. Caspofungin vs amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients:a multi-centre, randomized, double-blind study.  N Engl J Med. 2002;  347 2020-2029
  CrossrefPubMedGoogle Scholar
• 54 Kohler S, Wheat L J, Connolly P et al.. Comparison of the echinocandin, caspofungin, with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.  Antimicrob Agents Chemother. 2000;  44 1850-1854
  CrossrefPubMedGoogle Scholar
• 55 Graybill J R, Najvar L K, Montalbo E M et al.. Treatment of histoplasmosis with MK-0991 (L-743,872).  Antimicrob Agents Chemother. 1998;  42 151-153
  PubMedGoogle Scholar
• 56 Gonzalez G M, Tijerina R, Najvar L K et al.. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model.  Antimicrob Agents Chemother. 2001;  45 1854-1859
  CrossrefPubMedGoogle Scholar

Carol A KauffmanM.D. 

Infectious Diseases Section, Veterans Affairs Ann Arbor Healthcare System, University of Michigan Medical Center

2215 Fuller Rd.

Ann Arbor, MI 48105

Email: ckauff@umich.edu